Atlantic Union Bankshares Corp Has $925,000 Holdings in Edwards Lifesciences Corporation $EW

Atlantic Union Bankshares Corp raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2,240.9% in the third quarter, HoldingsChannel reports. The fund owned 11,892 shares of the medical research company’s stock after acquiring an additional 11,384 shares during the period. Atlantic Union Bankshares Corp’s holdings in Edwards Lifesciences were worth $925,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Rosenberg Matthew Hamilton acquired a new position in Edwards Lifesciences in the 2nd quarter valued at $28,000. True Wealth Design LLC boosted its position in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares during the period. NewSquare Capital LLC grew its stake in shares of Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares in the last quarter. Rakuten Securities Inc. increased its position in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the period. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in Edwards Lifesciences in the 3rd quarter worth about $30,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on EW shares. BTIG Research restated a “buy” rating and set a $103.00 target price (up previously from $100.00) on shares of Edwards Lifesciences in a research report on Thursday, December 4th. The Goldman Sachs Group restated a “buy” rating and set a $108.00 price objective on shares of Edwards Lifesciences in a research note on Friday, January 9th. Truist Financial set a $92.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, December 5th. Piper Sandler reissued an “overweight” rating and set a $98.00 target price (up from $95.00) on shares of Edwards Lifesciences in a report on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $96.77.

Edwards Lifesciences Trading Down 2.9%

Shares of EW opened at $79.75 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The firm has a market cap of $46.28 billion, a price-to-earnings ratio of 34.38, a PEG ratio of 3.16 and a beta of 0.94. The business’s fifty day moving average is $84.48 and its 200-day moving average is $81.10.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the transaction, the vice president directly owned 38,970 shares of the company’s stock, valued at $3,264,127.20. This trade represents a 22.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 57,824 shares of company stock worth $4,863,323 over the last 90 days. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.